Medtronic (MDT) Cash from Financing Activities (2014 - 2026)

Medtronic has reported Cash from Financing Activities for 13 years, with the latest figure at -$888.0 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 33.88% year-over-year to -$888.0 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was -$4.8 billion (down 8.94% YoY) and the FY2026 annual result came in at -$4.8 billion, down 8.94% from the prior year.
• Cash from Financing Activities climbed to -$888.0 million in Q2 2026 per MDT's latest filing, from -$2.1 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $3.0 billion in Q4 2022 and troughed at -$4.9 billion in Q2 2023.
• A 5-year average of -$1.2 billion and a median of -$1.3 billion in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities soared 360.95% in 2022, then tumbled 493.33% in 2024.
• Over 5 years, Cash from Financing Activities stood at $3.0 billion in 2022, then sank by 102.99% to -$90.0 million in 2023, then sank by 493.33% to -$534.0 million in 2024, then grew by 26.03% to -$395.0 million in 2025, then tumbled by 124.81% to -$888.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$888.0 million, -$2.1 billion, and -$395.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.